David Loewenstein, Ph.D., Addresses NIH Summit on Alzheimer’s Disease
The Miller School’s David Loewenstein, Ph.D., was invited to speak at an international research summit hosted by the U.S. Department of Health and Human Services and the National Institute on Aging on the treatment and prevention of Alzheimer’s disease.
The goal of the “Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention,” held May 14-15 at the National Institutes of Health in Bethesda, Maryland, was to identify the research priorities and strategies needed to accelerate the development of successful therapies for Alzheimer’s across the disease continuum.
An authority on novel cognitive and functional interventions, Loewenstein, professor of psychiatry and behavioral sciences and a member of the UM Center on Aging faculty, discussed promising prevention and treatment options, including exercise and cognitive training, for a session on non-pharmacological interventions.
He also addressed major questions on how to integrate findings from epidemiology and basic and translational research and develop an effective non-pharmacologic therapeutic regimen, and the difficulties involved, such as patient and caregiver burdens.
“I think this summit resulted in recommendations that will guide our national efforts to combat Alzheimer’s disease in terms of prevention and treatment,” said Loewenstein.
Attended by an international group of about 500 researchers, clinicians and members of the broader Alzheimer’s community, the summit was organized in response to the National Alzheimer’s Project Act. Signed by President Obama last year, the law calls for a national plan to coordinate research and services across all federal agencies, accelerate the development of treatments, improve early diagnosis, coordination of care and outcomes for at-risk populations, and collaborate on international efforts to fight Alzheimer’s disease and related dementias globally.